Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
March 19, 2025 04:00 ET | Source: Oxford BioTherapeutics Collaboration leverages OBT’s…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025 17:00 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025 17:00 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024 12:00 ET | Source: Affimed N.V. The combination of…